This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Astrazeneca Ab. Active years: 2005.
Company Filing History:
Years Active: 2005
Title: Robert Jewell: Innovator in Chemokine Receptor Modulation
Introduction
Robert Jewell is a notable inventor based in Loughborough, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that modulate chemokine receptor activity. His work is crucial in addressing various inflammatory diseases.
Latest Patents
Robert Jewell holds a patent for "Thiazolopyrimidines and their use as modulators of chemokine receptor activity." This patent describes compounds of formula (I) that can be utilized in the treatment of chemokine-mediated diseases, including inflammatory conditions such as psoriasis and chronic obstructive pulmonary disease (COPD). His innovative approach offers potential therapeutic avenues for patients suffering from these ailments.
Career Highlights
Throughout his career, Robert has been associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to collaborate with other talented professionals in the field, enhancing the impact of his research.
Collaborations
Robert Jewell has worked alongside esteemed colleagues such as Roger Victor Bonnert and Peter Cage. Their combined expertise has contributed to advancements in the understanding and treatment of chemokine-related diseases.
Conclusion
Robert Jewell's contributions to the field of medicinal chemistry, particularly through his patent on thiazolopyrimidines, highlight his role as an innovator in the treatment of inflammatory diseases. His work continues to pave the way for new therapeutic strategies.